Buprenorphine for probationers and parolees: Bridging the gap into treatment

丁丙诺啡用于缓刑犯和假释犯：缩小治疗差距

• 批准号: 9898338
• 负责人: Michael Scott Gordon
• 金额: $ 62.84万
• 依托单位: FRIENDS RESEARCH INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-15 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9898338
• 关键词: Adult; Area; Awareness; Baltimore; Buprenorphine; Caring; Cities; Communities; Counseling; Criminal Justice; Devices; Drug usage; Effectiveness; Frequencies; Funding; Gender; HIV risk; Imprisonment; Individual; Intake; Intervention; Intravenous; Link; Location; Medical; Mental Health; Methadone; Modeling; National Institute of Drug Abuse; Needles; Opioid; Participant; Patients; Pharmaceutical Preparations; Pharmacotherapy; Pilot Projects; Placebos; Population; Public Health; Publishing; Quality of life; Randomized; Randomized Controlled Trials; Reporting; Research; Risk Behaviors; Safety; Sex Behavior; Site; Supervision; Surveys; Test Result; United States; Urine; Waiting Lists; Woman; buprenorphine treatment; community setting; criminal behavior; design; effectiveness evaluation; heroin overdose; heroin use; high risk population; illicit opioid; innovation; men; methadone treatment; opioid agonist therapy; opioid use; opioid use disorder; outpatient programs; overdose prevention; parole; parolee; patient population; physical conditioning; prescription opioid misuse; probation; probationer; programs; reincarceration; relative effectiveness; scale up; treatment as usual; treatment program; treatment services

ABSTRACT This proposed five-year study will evaluate the effectiveness of the administration of buprenorphine bridge treatment (BBT) to probationers and parolees compared to treatment as usual (TAU), which consists of referral to a community buprenorphine treatment program. Project implementation will occur at Guilford Avenue, the primary intake unit for Baltimore City Community Supervision (Probation and Parole). The proposed study is a parallel two-group randomized controlled trial in which 160 men and 160 women with OUD on community supervision in Baltimore will be randomly assigned within community supervision status (probation or parole) and gender to one of two treatment conditions: (1) Buprenorphine Bridge Treatment (BBT): Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment; or (2) Treatment as Usual (TAU): Participants will receive a referral to buprenorphine treatment in the community. Both conditions will receive information on overdose prevention. Participants will be assessed at baseline, and 1, 2, 3, 6, and 12 months post-intake using a comprehensive assessment battery. The Primary Aim: To compare the relative effectiveness of BBT to TAU in terms of: (a) illicit opioid urine test results. The Secondary Aim: To examine the extent to which BBT is superior to TAU in terms of: (b) number of days receiving opioid treatment; (c) number of days using illicit opioids; (d) quality of life (i. physical health; ii. mental health); (e) HIV risk behaviors (i. sexual behavior; ii. needle use or sharing); (f) criminal activity; (g) re-arrest; and (h) re-incarceration. The proposed study is significant because the large number of probationers/parolees with OUD have limited access to an efficacious treatment, buprenorphine pharmacotherapy. The proposed study is innovative because it would be the first trial in the US assessing the effectiveness of interim buprenorphine initiated at a community supervision office compared to referral to a community treatment program. The public health impact would be widespread, as this model of care could be scaled-up throughout many areas of the US with criminal justice populations with high rates of OUD.

抽象的 这项拟议的五年研究将评估管理的有效性 与治疗相比 通常（TAU），包括转介到社区丁丙诺啡治疗计划。 项目实施将在巴尔的摩市的主要进气门吉尔福德大街发生 社区监督（缓刑和假释）。拟议的研究是平行的两组 随机对照试验中，有160名男性和160名妇女在社区中 巴尔的摩的监督将在社区监督状态中随机分配 （试用或假释）和性别达到两个治疗条件之一：（1）丁丙诺啡桥 治疗（BBT）：参与者将使用Medicasafe开始丁丙诺啡药物治疗 在社区现场摄入后，丁丙诺啡分配设备立即 监督办公室并继续进行此类治疗，直到它们过渡到社区 丁丙诺啡治疗；或（2）照常治疗（tau）：参与者将收到转诊 社区中的丁丙诺啡治疗。两种情况都将收到过量的信息 预防。参与者将在基线时进行评估，并在入场后1、2、3、6和12个月进行评估 使用全面的评估电池。主要目的：比较亲戚 BBT对tau的有效性以：（a）非法阿片类药物尿液测试结果。次要目的： 检查BBT在多大程度上优于TAU的程度：（b）接受的天数 阿片类药物治疗； （c）使用非法阿片类药物的天数； （d）生活质量（i。身体健康； ii。 心理健康）； （e）艾滋病毒风险行为（i。性行为；ii。针头使用或共享）； （f）罪犯 活动; （g）重新逮捕； （h）重新监禁。拟议的研究很重要，因为大 试用者/假释者的数量有限地获得有效治疗， 丁丙诺啡药物疗法。拟议的研究具有创新性，因为它将是第一个 在美国评估社区发起的临时丁丙诺啡的有效性 监督办公室与转介到社区治疗计划相比。公共卫生 影响将是广泛的，因为这种护理模型可以在许多领域进行扩展 美国的刑事司法人口较高。